{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:43:54Z","timestamp":1762505034239},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[1990,5,1]],"date-time":"1990-05-01T00:00:00Z","timestamp":641520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drug Ther"],"published-print":{"date-parts":[[1990,5]]},"DOI":"10.1007\/bf01856555","type":"journal-article","created":{"date-parts":[[2005,6,30]],"date-time":"2005-06-30T21:57:57Z","timestamp":1120168677000},"page":"681-685","source":"Crossref","is-referenced-by-count":6,"title":["Propafenone in Wolff-Parkinson-White syndrome at risk"],"prefix":"10.1007","volume":"4","author":[{"given":"Vincenzo","family":"Santinelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Turco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"De Paola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Smimmo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Giasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Crescenzo","family":"Santinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Chiariello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Condorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF01856555_CR1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0735-1097(84)80190-4","volume":"3","author":"EN Shoen","year":"1984","unstructured":"Shoen EN, Sung RJ, Morady F, et al. Electrophysiologic and hemodynamic effects of intravenous propafenone in patients with recurrent ventricular tachycardia.J Am Coll Cardiol 1984;3:1291\u20131297.","journal-title":"J Am Coll Cardiol"},{"key":"BF01856555_CR2","doi-asserted-by":"crossref","first-page":"26D","DOI":"10.1016\/S0002-9149(84)80282-9","volume":"54","author":"EN Prystowsky","year":"1984","unstructured":"Prystowsky EN, Heger JJ, Chilson DA, et al. Antiarrhythmic and electrophysiologic effects of oral propafenone.Am J Cardiol 1984;54:26D-28D.","journal-title":"Am J Cardiol"},{"key":"BF01856555_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0735-1097(84)80328-9","volume":"4","author":"PJ Podrid","year":"1984","unstructured":"Podrid PJ, Lown B. Propafenone: A new agent for ventricular arrhythmias.J Am Coll Cardiol 1984;4:117\u2013125.","journal-title":"J Am Coll Cardiol"},{"key":"BF01856555_CR4","doi-asserted-by":"crossref","first-page":"60D","DOI":"10.1016\/S0002-9149(84)80288-X","volume":"54","author":"P Coumel","year":"1984","unstructured":"Coumel P, Leclerq JF, Assayag P. European experience with the antiarrhythmic efficacy of propafenone for supraventricular and ventricular arrhythmias.Am J Cardiol 1984;54:60D-66D.","journal-title":"Am J Cardiol"},{"key":"BF01856555_CR5","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1540-8159.1984.tb05591.x","volume":"8","author":"R Garcia-Civera","year":"1984","unstructured":"Garcia-Civera R, Sarujuan R, Morell S, et al. Effects of propafenone on induction and maintenance of atrioventricular nodal reentrant tachycardia.PACE 1984;8:649\u2013655.","journal-title":"PACE"},{"key":"BF01856555_CR6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0735-1097(87)80478-3","volume":"9","author":"PL Ludmer","year":"1987","unstructured":"Ludmer PL, McGowan NE, Antman EM, et al. Efficacy of propafenone in WPW syndrome: Electrophysiologic findings and long-term follow-up.J. Am Coll Cardiol 1987;9:1357\u20131363.","journal-title":"J. Am Coll Cardiol"},{"key":"BF01856555_CR7","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S0735-1097(87)80479-5","volume":"9","author":"SC Hammill","year":"1987","unstructured":"Hammill SC, McLaren CJ, Wood DL, et al. Double-bind study of intra-venous propafenone for paroxysmal supraventricular reentrant tachycardia.J Am Coll Cardiol 1987;9:1364\u20131368.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 11","key":"BF01856555_CR8","first-page":"136","volume":"31","author":"V Santinelli","year":"1986","unstructured":"Santinelli V, De Paola M, Turco P, et al. Propafenone in patients with WPW at risk (preliminary results). XLVII National Congress of the Italian Society of Cardiology, Roma 16\u201320 December, 1986.Cardiologia 1986;31(Suppl 11):136.","journal-title":"Cardiologia"},{"key":"BF01856555_CR9","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0735-1097(98)90076-6","volume":"11","author":"V Santinelli","year":"1988","unstructured":"Santinelli V, De Paola M, Turco P, et al. WPW at risk and propafenone (letter).J Am Coll Cardiol 1988;11:1138.","journal-title":"J Am Coll Cardiol"},{"key":"BF01856555_CR10","first-page":"461","volume":"228","author":"AA McLeon","year":"1984","unstructured":"McLeon AA, Stiles GL, Shand DG. Demonstration of beta adrenoreceptor blockade by propafenone hydrochloride: Clinical, pharmacologic, radiologic and binding and adenylate cyclase activation studies.J Pharmacol Exp Ther 1984; 228:461\u2013466.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF01856555_CR11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/oxfordjournals.eurheartj.a061472","volume":"4","author":"HNJ Buss","year":"1983","unstructured":"Buss HNJ, Schlepper M, Berthold R, et al. Effects of flecainide on electrophysiological properties of accessory pathway in the WPW syndrome.Eur Heart J 1983;4:347\u2013353.","journal-title":"Eur Heart J"},{"key":"BF01856555_CR12","first-page":"531","volume":"33","author":"C Klersy","year":"1988","unstructured":"Klersy C, Marangoni E, Salerno JA, et al. Acute intravenous flecainide in WPW syndrome: A test for evaluation of the refractory period of the anomalous pathway. Comparison with ajmaline.Cardiologia 1988;33:531\u2013535.","journal-title":"Cardiologia"},{"issue":"Suppl","key":"BF01856555_CR13","first-page":"1216","volume":"64","author":"E Rowland","year":"1981","unstructured":"Rowland E, McKenna W, Holt D, et al. Control of ventricular response with oral amiodarone in patients with rapidly conducted atrial fibrillation complicating the WPW syndrome (abstract).Circulation 1981;64(Suppl):1216.","journal-title":"Circulation"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01856555.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01856555\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01856555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T21:37:04Z","timestamp":1557437824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01856555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1990,5]]}},"alternative-id":["BF01856555"],"URL":"https:\/\/doi.org\/10.1007\/bf01856555","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,5]]}}}